JP5607357B2 - 抗原特異的ｂ細胞のクローン集団を獲得するための培養方法 - Google Patents

抗原特異的ｂ細胞のクローン集団を獲得するための培養方法 Download PDF

Info

Publication number
JP5607357B2
JP5607357B2 JP2009512060A JP2009512060A JP5607357B2 JP 5607357 B2 JP5607357 B2 JP 5607357B2 JP 2009512060 A JP2009512060 A JP 2009512060A JP 2009512060 A JP2009512060 A JP 2009512060A JP 5607357 B2 JP5607357 B2 JP 5607357B2
Authority
JP
Japan
Prior art keywords
antigen
cells
antibody
cell
specific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009512060A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009537176A (ja
JP2009537176A5 (enExample
Inventor
ガルシア，レオン
ジェンセン，アン・エリザベス・カルヴァルホ
オジャラ，イーサン
ラサム，ジョン
Original Assignee
アルダー・バイオファーマシューティカルズ・インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39283142&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5607357(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by アルダー・バイオファーマシューティカルズ・インコーポレーテッド filed Critical アルダー・バイオファーマシューティカルズ・インコーポレーテッド
Publication of JP2009537176A publication Critical patent/JP2009537176A/ja
Publication of JP2009537176A5 publication Critical patent/JP2009537176A5/ja
Application granted granted Critical
Publication of JP5607357B2 publication Critical patent/JP5607357B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2009512060A 2006-05-19 2007-05-21 抗原特異的ｂ細胞のクローン集団を獲得するための培養方法 Expired - Fee Related JP5607357B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80141206P 2006-05-19 2006-05-19
US60/801,412 2006-05-19
PCT/US2007/011980 WO2008045140A1 (en) 2006-05-19 2007-05-21 Culture method for obtaining a clonal population of antigen-specific b cells

Publications (3)

Publication Number Publication Date
JP2009537176A JP2009537176A (ja) 2009-10-29
JP2009537176A5 JP2009537176A5 (enExample) 2010-07-08
JP5607357B2 true JP5607357B2 (ja) 2014-10-15

Family

ID=39283142

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009512060A Expired - Fee Related JP5607357B2 (ja) 2006-05-19 2007-05-21 抗原特異的ｂ細胞のクローン集団を獲得するための培養方法

Country Status (12)

Country Link
US (3) US20070269868A1 (enExample)
EP (1) EP2021463B1 (enExample)
JP (1) JP5607357B2 (enExample)
CN (1) CN101600793B (enExample)
AU (1) AU2007307324B2 (enExample)
CA (1) CA2652392C (enExample)
DK (1) DK2021463T3 (enExample)
IL (1) IL195285A (enExample)
MX (1) MX2008014692A (enExample)
NO (1) NO20084835L (enExample)
NZ (1) NZ572807A (enExample)
WO (1) WO2008045140A1 (enExample)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8252286B2 (en) 2007-05-21 2012-08-28 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US8178101B2 (en) 2007-05-21 2012-05-15 Alderbio Holdings Inc. Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
US8062864B2 (en) 2007-05-21 2011-11-22 Alderbio Holdings Llc Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
US8404235B2 (en) 2007-05-21 2013-03-26 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
KR101829776B1 (ko) 2007-05-21 2018-02-19 앨더바이오 홀딩스 엘엘씨 Ｉｌ-６에 대한 항체 및 이의 용도
US9701747B2 (en) 2007-05-21 2017-07-11 Alderbio Holdings Llc Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
US7906117B2 (en) 2007-05-21 2011-03-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
US8420089B2 (en) 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
US9452227B2 (en) 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
US8337847B2 (en) 2008-11-25 2012-12-25 Alderbio Holdings Llc Methods of treating anemia using anti-IL-6 antibodies
US8323649B2 (en) 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
WO2010065077A2 (en) * 2008-11-25 2010-06-10 Alder Biopharmaceuticals, Inc. Antagonists of il-6 to prevent or treat thrombosis
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US9079942B2 (en) * 2009-02-09 2015-07-14 Epitomics, Inc. CDR-anchored amplification method
US20100317539A1 (en) * 2009-06-12 2010-12-16 Guo-Liang Yu Library of Engineered-Antibody Producing Cells
IN2012DN01920A (enExample) 2009-09-03 2015-07-24 Schering Corp
US8293483B2 (en) 2009-09-11 2012-10-23 Epitomics, Inc. Method for identifying lineage-related antibodies
US9775921B2 (en) 2009-11-24 2017-10-03 Alderbio Holdings Llc Subcutaneously administrable composition containing anti-IL-6 antibody
EP2504030A4 (en) 2009-11-24 2013-06-26 Alderbio Holdings Llc IL-6 ANTAGONISTS FOR INCREASING ALBUMIN AND / OR REDUCING CRP
TWI667346B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的FcRn親和力之抗體
SI2400298T1 (sl) 2010-05-28 2013-11-29 F. Hoffmann-La Roche Ag Postopek kultivacije posamezne B-celice in izdelava specifičnih protiteles
AU2011332817A1 (en) 2010-11-23 2013-06-13 Alder Biopharmaceuticals, Inc. Anti-IL-6 antibodies for the treatment of anemia
NZ611076A (en) 2010-12-01 2015-09-25 Alderbio Holdings Llc Anti-ngf compositions and use thereof
JP5963746B2 (ja) * 2011-03-30 2016-08-03 国立大学法人富山大学 形質細胞または形質芽細胞の選択方法、目的抗原特異的な抗体の製造方法、新規モノクローナル抗体
JP6374789B2 (ja) 2011-05-20 2018-08-15 アルダーバイオ・ホールディングズ・エルエルシー 羞明または光嫌悪症を予防または抑制する抗ｃｇｒｐ抗体および抗体断片のそれを必要とする対象、特に片頭痛患者における使用
SG10201604040PA (en) 2011-05-20 2016-07-28 Alderbio Holdings Llc Anti-cgrp compositions and use thereof
CN103957935B (zh) 2011-05-20 2018-04-03 奥尔德生物控股有限责任公司 抗cgrp或抗cgrp‑r抗体或抗体片段用于治疗或预防慢性和急性形式的腹泻的用途
EP2724157B1 (en) * 2011-06-27 2017-03-08 Valneva Method for screening cells
US11782053B2 (en) * 2011-09-28 2023-10-10 iRepertoire, Inc. Identification of antigen-specific adaptive immune responses using ARM-PCR and high-throughput sequencing
JP6374791B2 (ja) 2011-11-23 2018-08-15 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｃｄ４０ｌ発現哺乳動物細胞およびその使用
MX354049B (es) 2011-12-21 2018-02-09 Hoffmann La Roche Método rápido para la clonación y expresión de segmentos génicos de regiones variables de anticuerpos cognados.
EP2727942A1 (en) 2012-11-05 2014-05-07 MAB Discovery GmbH Bispecific antibodies against human EGFR, HER2, and HER3
EP2727941A1 (en) 2012-11-05 2014-05-07 MAB Discovery GmbH Method for the production of multispecific antibodies
WO2014067642A1 (en) 2012-11-05 2014-05-08 Mab Discovery Gmbh Method for the production of multispecific antibodies
EP2727943A1 (en) 2012-11-05 2014-05-07 MAB Discovery GmbH Trispecific antibodies against human EGFR, HER2 and HER3
BR112015010360A8 (pt) 2012-11-08 2018-01-16 Eleven Biotherapeutics Inc antagonistas de il-6 e utilização dos mesmos.
CN104822828A (zh) * 2012-11-13 2015-08-05 弗·哈夫曼-拉罗切有限公司 抗原特异性浆母细胞的富集
EP2956478A1 (en) * 2013-02-15 2015-12-23 ESBATech - a Novartis Company LLC Acceptor framework for cdr grafting
WO2014153166A2 (en) * 2013-03-14 2014-09-25 Alder Biopharmaceuticals, Inc. Therapeutic use of antibodies to hgf
CA2907570A1 (en) * 2013-03-15 2014-09-18 Alder Biopharmaceuticals, Inc. Protocol for identifying and isolating antigen-specific b cells and producing antibodies to desired antigens
EP3754012A1 (en) 2013-03-15 2020-12-23 Alder Biopharmaceuticals, Inc. Antibody purification and purity monitoring
JP6412552B2 (ja) 2013-03-15 2018-10-24 アルダー・バイオファーマシューティカルズ・インコーポレーテッド 酵母及び他の形質転換細胞中のポリペプチドの高収率発現のための温度シフト
US20160075766A1 (en) 2013-05-21 2016-03-17 Roche Diagnostics Operations, Inc. Method for producing antibodies using ovine b-cells and uses thereof
CN104232577B (zh) * 2013-06-20 2017-12-01 中国人民解放军军事医学科学院基础医学研究所 一种获得自身反应性b细胞的方法
MX374612B (es) 2013-07-03 2025-03-06 H Lundbeck As Star Regulacion del metabolismo de glucosa usando anticuerpos anti-cgrp.
UA122673C2 (uk) 2014-11-07 2020-12-28 Елевен Байотерапьютікс, Інк. Антитіло, що специфічно зв'язується з людським il-6
WO2016149137A1 (en) * 2015-03-18 2016-09-22 Epitomics, Inc. High throughput monoclonal antibody generation by b cell panning and proliferation
EP3305325B1 (en) 2015-06-04 2025-07-30 National Center of Neurology and Psychiatry Mental illness therapeutic agent having il-6 inhibitor as active ingredient
US10906971B2 (en) 2015-06-26 2021-02-02 Sanofi Biotechnology SAS Monoclonal anti-IL-1RAcP antibodies
JP2019510078A (ja) 2016-02-23 2019-04-11 セセン バイオ， インコーポレイテッド Ｉｌ−６アンタゴニスト製剤およびその使用
EP4273232A3 (en) 2016-03-30 2024-01-03 F. Hoffmann-La Roche AG B-cell cultivation method
JP2019515671A (ja) 2016-04-15 2019-06-13 アルダー バイオファーマシューティカルズ、インコーポレイテッド 抗ｐａｃａｐ抗体及びそれらの使用
EP3241845A1 (en) 2016-05-06 2017-11-08 MAB Discovery GmbH Humanized anti-il-1r3 antibodies
CN106350485B (zh) * 2016-08-24 2020-02-21 杭州百凌生物科技有限公司 一种快速高效分离单个抗原特异性b细胞的方法
CN110121554B (zh) 2017-01-02 2023-08-15 豪夫迈·罗氏有限公司 B细胞培养方法
EP3401332A1 (en) 2017-05-08 2018-11-14 MAB Discovery GmbH Anti-il-1r3 antibodies for use in inflammatory conditions
EP3625332B1 (en) 2017-05-19 2022-02-02 F. Hoffmann-La Roche AG Method for the production of thymocyte supernatant
US11125757B2 (en) * 2017-05-26 2021-09-21 Emory University Methods of culturing and characterizing antibody secreting cells
EP3717632B1 (en) 2017-11-30 2022-10-26 F. Hoffmann-La Roche AG B-cell cultivation method
AU2019270181B2 (en) * 2018-05-18 2023-06-01 Cz Biohub Sf, Llc Methods of isolating allergen-specific antibodies from humans and uses thereof
CN114144436A (zh) 2019-07-24 2022-03-04 H.隆德贝克有限公司 抗mGluR5抗体及其用途
JP2023106635A (ja) 2020-04-17 2023-08-02 中外製薬株式会社 二重特異性抗原結合分子ならびに、それに関連する組成物、組成物の製造のための使用、キット、および方法
WO2022004620A1 (ja) * 2020-06-29 2022-01-06 株式会社Npt 抗原特異的抗体産生細胞を含む組成物の製造方法、ワクチン組成物の製造方法、細胞分離キットおよびワクチン組成物
WO2022192625A1 (en) 2021-03-11 2022-09-15 IgGenix, Inc. Methods and systems for predicting allergic response
WO2022241415A1 (en) * 2021-05-11 2022-11-17 Yale University Methods for monoclonal antibody generation
KR20250060305A (ko) 2022-09-21 2025-05-07 사노피 바이오테크놀로지 인간화 항-il-1r3 항체 및 사용 방법

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6657103B1 (en) * 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
AU7796291A (en) * 1990-05-04 1991-11-27 Baxter Diagnostics Inc. High affinity antibodies to small peptides
WO1992002551A1 (en) 1990-08-02 1992-02-20 B.R. Centre Limited Methods for the production of proteins with a desired function
ZA919299B (en) * 1990-11-26 1992-08-26 Akzo Nv Method for the production of antibodies
US6277969B1 (en) * 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US5256542A (en) * 1992-03-09 1993-10-26 Tanox Biosystems, Inc. Selecting low frequency antigen-specific single B lymphocytes with correction for background noise
US6972125B2 (en) * 1999-02-12 2005-12-06 Genetics Institute, Llc Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
RU2318829C2 (ru) * 2001-11-14 2008-03-10 Сентокор, Инк. Антитела против il-6, композиции, способы и применение
US20040185040A1 (en) * 2001-11-21 2004-09-23 Celltech R & D Limited Modulating immune responses
US8188231B2 (en) * 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
CA2507004A1 (en) 2002-12-03 2004-06-17 Celltech R & D Limited Assay for identifying antibody producing cells
GB0312481D0 (en) * 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
WO2005016950A1 (en) * 2003-08-07 2005-02-24 Epitomics, Inc. Methods for humanizing rabbit monoclonal antibodies
EP1658498A1 (en) 2003-08-20 2006-05-24 Celltech R & D Limited Methods for obtaining antibodies
EP1658500B1 (en) 2003-08-20 2012-04-18 UCB Pharma, S.A. Methods for obtaining antibodies
CN1871259A (zh) * 2003-08-22 2006-11-29 比奥根艾迪克Ma公司 具有改变的效应物功能的经改进的抗体和制备它的方法
WO2005020924A2 (en) * 2003-08-29 2005-03-10 Centocor, Inc. A rapid way to obtain high expression clones of mammalian cells using a methylcellulose and immunoprecipitation screening method
ES2630224T3 (es) * 2003-10-22 2017-08-18 Keck Graduate Institute Métodos para sintetizar polipéptidos heteromultiméricos en levadura con el uso de una estrategia de apareamiento haploide
GB0412973D0 (en) 2004-06-10 2004-07-14 Celltech R&D Ltd Identification of antibody producing cells
US20060051348A1 (en) * 2004-09-09 2006-03-09 Jorn Gorlach Method of producing a plurality of isolated antibodies to a plurality of cognate antigens
US7968308B2 (en) * 2004-10-22 2011-06-28 Danisco Us Inc. Isolating human antibodies
US7462697B2 (en) * 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
GB0425972D0 (en) 2004-11-25 2004-12-29 Celltech R&D Ltd Biological products
PA8672101A1 (es) * 2005-04-29 2006-12-07 Centocor Inc Anticuerpos anti-il-6, composiciones, métodos y usos
US20070092943A1 (en) * 2005-09-28 2007-04-26 The University Of Chicago Versatile vectors for expression of foreign proteins in photosynthetic bacteria

Also Published As

Publication number Publication date
AU2007307324A1 (en) 2008-04-17
EP2021463B1 (en) 2016-11-23
US20130316353A1 (en) 2013-11-28
IL195285A (en) 2012-07-31
CN101600793A (zh) 2009-12-09
CA2652392A1 (en) 2008-04-17
JP2009537176A (ja) 2009-10-29
CA2652392C (en) 2017-10-10
MX2008014692A (es) 2009-08-18
CN101600793B (zh) 2013-06-26
EP2021463A1 (en) 2009-02-11
NZ572807A (en) 2011-10-28
IL195285A0 (en) 2011-08-01
AU2007307324B2 (en) 2013-08-15
EP2021463A4 (en) 2009-09-02
US20070269868A1 (en) 2007-11-22
DK2021463T3 (en) 2017-01-16
WO2008045140A1 (en) 2008-04-17
NO20084835L (no) 2009-02-16
US20120141982A1 (en) 2012-06-07

Similar Documents

Publication Publication Date Title
JP5607357B2 (ja) 抗原特異的ｂ細胞のクローン集団を獲得するための培養方法
JP6466397B2 (ja) 抗原特異的ｂ細胞の同定及び単離ならびに所望の抗原に対する抗体作製のプロトコール
AU2016203162B2 (en) Comprehensive monoclonal antibody generation
EP2724157B1 (en) Method for screening cells
AU2009274502A1 (en) Methods and compositions for discovery of target-specific antibodies using antibody repertoire array (ARA)
US10934524B2 (en) High throughput monoclonal antibody generation by B cell panning and proliferation
WO2018122147A1 (en) B-cell cultivation method
HK1127372B (en) Culture method for obtaining a clonal population of antigen-specific b cells
HK1127372A (en) Culture method for obtaining a clonal population of antigen-specific b cells
Zhai et al. Monoclonal Antibody Development Technology for Important Human Diseases
WO2022162009A1 (en) Method for rapid identification of cross-reactive and/or rare antibodies
WO2022161597A1 (en) Method for rapid identification of cross-reactive and/or rare antibodies
JP5246859B2 (ja) 抗体産生細胞の誘導又は活性化方法
HK1231888B (zh) 全面单克隆抗体产生

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100521

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100521

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121121

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130219

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130226

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130313

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130321

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130520

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131120

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140219

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140221

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140226

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140515

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140730

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140828

R150 Certificate of patent or registration of utility model

Ref document number: 5607357

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees